| 释义 |
Cabergoline
基本例句
卡麦角林抑乳药
Conclusions In this study, use of the dopamine agonists pergolide andcabergolinewas associated with an increased risk of newly diagnosed cardiac-valve regurgitation.结论：研究发现使用多巴胺受体激动剂培高利特和卡麦角林可增加新发生的心脏瓣膜返流的风险。
In this study, use of the dopamine agonists pergolide andcabergolinewas associated with an increased risk of newly diagnosed cardiac-valve regurgitation.研究发现使用多巴胺受体激动剂培高利特和卡麦角林可增加新发生的心脏瓣膜返流的风险。
Conclusions In this study, use of the dopamine agonists pergolide andcabergolinewas associated with an increased risk of newly diagnosed cardiac-ale regurgitation.结论：研究发现使用多巴胺受体激动剂培高利特和卡麦角林可增加新发生的心脏瓣膜返流的风险。
Results Of31 case patients with newly diagnosed cardiac-valve regurgitation,6 were currently exposed to pergolide,6 were currently exposed tocabergoline, and19 had not been exposed to any dopamine agonist within the previous year.结果：有31例患者出现新诊断的心脏瓣膜返流，其中6例研究时正在服用培高利特，6例使用卡麦角林，另外19例在研究的前一年中未再使用任何多巴胺受体激动剂。
Of 31 case patients with newly diagnosed cardiac-valve regurgitation, 6 were currently exposed to pergolide, 6 were currently exposed tocabergoline, and 19 had not been exposed to any dopamine agonist within the previous year.有31例患者出现新诊断的心脏瓣膜返流，其中6例研究时正在服用培高利特，6例使用卡麦角林，另外19例在研究的前一年中未再使用任何多巴胺受体激动剂。
The frequency of clinically important valve regurgitation was significantly increased in patients taking pergolide orcabergoline, but not in patients taking non?ergot-derived dopamine agonists, as compared with control subjects.与对照组相比，服用培高利特或者卡麦角林的患者临床上发生重要瓣膜返流的频率显著增加，但服用非麦角??生的多巴胺受体激动剂的患者瓣膜返流的发生率却未增加。 |